Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASH: Piperacillin-tazobactam vs Cefuroxime for Prophylaxis in Hepatobiliary Surgery
NCT07620223Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of piperacillin + tazobactam in surgical site infection (SSI) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Surgical site infection at 30 days. Started May 2026; status: recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT07620223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620223.